Pharmaceutical - Novo Nordisk, Asia-Pacific

Filter

Current filters:

Novo NordiskAsia-Pacific

Popular Filters

Novo Nordisk’s NovoEight passes first stage of Japanese approval

Novo Nordisk’s NovoEight passes first stage of Japanese approval

18-11-2013

Danish insulin giant Novo Nordisk’s recombinant factor VIII product NovoEight (turoctocog alfa) has…

Asia-PacificHematologyNovo NordiskNovoEightPharmaceuticalRare diseasesRegulation

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Sanofi latest to be implicated Chinese bribery allegations

09-08-2013

In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord

13-02-2013

Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin

24-01-2013

Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review

03-12-2012

Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Russia's Renova invests in Novelos; Novo Nordisk opens Vietnam office

08-11-2012

USA-based Novelos Therapeutics (OTCQX: NVLT), which is developing novel drugs for the treatment and diagnosis…

Asia-PacificDiabetesFinancialMarkets & MarketingNovelos TherapeuticsNovo NordiskOncologyPharmaceutical

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016

23-10-2012

The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

EMA panel backing for Novo Nordisk's Tresiba and Ryzodeg: Japanese review

22-10-2012

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday announced…

Asia-PacificDegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk invests $100 million for bigger R&D center in China

24-09-2012

Denmark's Novo Nordisk (NOV: N) said this morning that it is investing an additional $100 million to…

Asia-PacificFinancialNovo NordiskPharmaceuticalResearch

Novo Nordisk insulin degludec passes first regulatory hurdle in Japan

03-09-2012

Danish insulin giant Novo Nordisk (NOV: N) revealed on Friday that its ultra-long-acting insulin degludec…

Asia-PacificDegludecDiabetesNovo NordiskPharmaceuticalRegulation

New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit

02-05-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to fund…

Asia-PacificDiabetesGlucaGenNovo NordiskNovoMixNovoSevenPharmaceuticalPricingRegulation

Pfizer and Biocon cancel biosimilars deal

14-03-2012

Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan

22-12-2011

Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization…

Asia-PacificBiotie TherapiesDegludecDiabetesEuropeLundbeckNeurologicalNovo NordiskPharmaceuticalRegulationSelincro

AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza

10-10-2011

Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in…

Asia-PacificAstraZenecaDiabetesFinancialMarkets & MarketingNovo NordiskPharmaceuticalRegulationVictoza

Novo Nordisk extends free insulin and diabetes care program to India

07-09-2011

Denmark’s Novo Nordisk (NVO: N), the world’s largest insulin maker, yesterday launched its…

Asia-PacificDiabetesMarkets & MarketingNovo NordiskPharmaceutical

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top